Generated by AI
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious rare and ultra-rare genetic diseases. Its current portfolio includes Crysvita, an antibody treatment for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for mucopolysaccharidosis VII; Dojolvi, a nutritional therapy for long-chain fatty acid oxidation disorders; and Evkeeza, a treatment for homozygous familial hypercholesterolemia. The company also develops medicines across biologics, small molecules, gene therapy, and nucleic acid technologies, addressing conditions with limited treatment options. Ultragenyx Pharmaceutical Inc. serves patients and healthcare providers across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. Its role in the financial market reflects the specialized biopharmaceutical sector, where commercial products, regulatory expertise, manufacturing capabilities, and rare-disease research support access to targeted therapies and contribute to healthcare innovation.
Website60 Leveroni Court
Novato, CA, 94949
United States
The latest articles about RARE.
Ultragenyx Pharmaceutical's two major late-stage pipeline failures have reset investor sentiment. Find out why RARE stock is a Hold.
BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted on 28th October 2026 the Company’s Marketing Authorisation Application (MAA) for rebisufligene etisparvovec (also known as rebi-vec or UX111), an investigational gene therapy for the tre
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about RARE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.